AI assistant
MorphoSys AG Report Publication Announcement 2017
291_rns_2017-03-02_0dcaa5e8-2020-40cb-b682-086b461dee1a.html
Report Publication Announcement
Open in viewerOpens in your device viewer
News Details
Corporate | 2 March 2017 14:00
Invitation to Year-End Results 2016 Conference Call
DGAP-News: MorphoSys AG / Key word(s): Final Results
02.03.2017 / 14:00
The issuer is solely responsible for the content of this announcement.
Planegg/Munich, Germany, March 2, 2017
Invitation to Year-End Results 2016 Conference Call
of MorphoSys AG on March 9, 2017
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2016 on March 9, 2017 at 7:00 a.m. CET.
The Management team of MorphoSys AG will host a conference call and webcast to present MorphoSys’s Annual Financial Results 2016 and provide an outlook for 2017.
Date: Thursday, March 9, 2017
Time: 2:00 p.m. CET (1:00 p.m. GMT, 8:00 a.m. EST)
Dial-in numbers (listen only):
Germany: +49 89 2444 32975
United Kingdom: +44 20 3003 2666
USA: +1 202 204 1514
Company participants in the call will be:
Dr. Simon Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Malte Peters, Chief Development Officer
Dr. Marlies Sproll, Chief Scientific Officer
Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start.
The presentation slides and webcast link will be available at the Company’s website at www.morphosys.com/conference-calls
A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com .
HuCAL (R) , HuCAL GOLD (R) , HuCAL PLATINUM (R) , CysDisplay (R) , RapMAT (R) , arYla (R) , Ylanthia (R) , 100 billion high potentials (R) , Slonomics (R) , Lanthio Pharma (R) and LanthioPep (R) are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
02.03.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | MorphoSys AG |
| Semmelweisstr. 7 | |
| 82152 Planegg | |
| Germany | |
| Phone: | +49 (0)89 899 27-0 |
| Fax: | +49 (0)89 899 27-222 |
| E-mail: | [email protected] |
| Internet: | www.morphosys.com |
| ISIN: | DE0006632003 |
| WKN: | 663200 |
| Indices: | TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |